Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 4107943, 9 pages
Research Article

Cotransplantation of Mesenchymal Stem Cells and Immature Dendritic Cells Potentiates the Blood Glucose Control of Islet Allografts

1Department of Hepatobiliary Surgery, Peking University Shenzhen Hospital, Shenzhen, China
2Center Laboratory, Peking University Shenzhen Hospital, Shenzhen, China
3Shenzhen BioScien Pharmaceuticals Co. LTD, Shenzhen, China

Correspondence should be addressed to Yinke Yang; moc.qq@4072695752

Received 8 August 2017; Revised 23 October 2017; Accepted 21 November 2017; Published 19 December 2017

Academic Editor: Naoaki Sakata

Copyright © 2017 Guanghui Long et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Transplantation of islets is a promising alternative to treat type 1 diabetes (T1D), but graft rejection is the major obstacle to its application in clinical practice. We evaluated the effects of mesenchymal stem cells (MSCs) and immature dendritic cells (imDCs) on islet transplantation in diabetic model. Methods. The streptozotocin T1D model was established in BABL/c mice. Rat islets were isolated and identified with dithizone (DTZ) staining. MSCs and imDCs were isolated from bone marrow of syngenic mice. Islets, alone or along with MSCs and/or imDCs, were transplanted to the left kidney capsule of diabetic mice. The blood glucose levels and glycosylated hemoglobin levels after transplantation were monitored. Results. Cotransplantation significantly decreased blood glucose and glycosylated hemoglobin levels in the diabetes mice. Transplantation of 200 islets + 2 × 105 MSCs + 2 × 105 imDCs could not only restore normal blood glucose levels, but also significantly prolong graft survival for days. Conclusions. Cotransplantation of allogenic islets with imDCs and/or MSCs can significantly promote graft survival, reverse hyperglycemia, and effectively control the glycosylated hemoglobin levels.